Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder

References

• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Sutton VK, Calabrese JR, et al. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009;116:43-50
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-17
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 2008;69:1776-89
   PubMed Web of Science ®Google Scholar
• Niufan G, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008;105:101-8
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26
   PubMed Web of Science ®Google Scholar
• Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67:1747-53
   PubMed Web of Science ®Google Scholar
• Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kauer-Sant’Anna M, Bond DJ, et al. Course and outcome after the first manic episode in patients with bipolar disorder: prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project. Can J Psychiatry 2009;54:105-12
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93
   PubMed Web of Science ®Google Scholar
• Katagiri H, Takita Y, Tohen M, et al. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: A randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord 2012;136:476-484
   Google Scholar
• The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992
   Google Scholar
• Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003;5:407-20
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-56
   PubMed Web of Science ®Google Scholar
• Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547-56
   PubMed Web of Science ®Google Scholar
• Vieta E, Panicali F, Goetz I, et al. EMBLEM Advisory Board. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008;106:63-72
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
   PubMed Web of Science ®Google Scholar
• Houston JP, Tohen M, Degenhardt EK, et al. Olanzapine–divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70:1540-7
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192:135-43
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y. M.I.N.I. – Simple Structured Interview Method for Mental diseases. Otsubo T, Miyaoka H, Kamijima K, trans. Tokyo: Seiwa Shoten, 2000
   Google Scholar
• Inada, T. Assessment and Diagnosis of Drug-induced Extrapyramidal Symptoms; Explanation and Usage Guide of DIEPSS. Tokyo: Seiwa Shoten, 1996
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
   PubMed Web of Science ®Google Scholar
• Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-71
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004;65:1679-87
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-71
   PubMed Web of Science ®Google Scholar
• Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-87
   PubMed Web of Science ®Google Scholar
• Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic–depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-67
   PubMedGoogle Scholar
• White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-22
   PubMed Web of Science ®Google Scholar
• Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990;5:217-25
   PubMed Web of Science ®Google Scholar
• Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60(Suppl 1):16-9
   PubMed Web of Science ®Google Scholar